Tranexamic Acid in Lower Extremity Endoprosthetic Reconstruction for Oncologic Indications: A Retrospective Comparative Study of 617 Patients - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Use of Tranexamic Acid in Oncologic Lower Limb Endoprosthetic Reconstruction: A Retrospective Analysis of 617 Cases

  • By

  • Stephen W. Chenard

  • Akhil Rekulapelli

  • Riley S. Gilbertson

  • Connor S. Charton

  • William F. Hefley

  • Michael J. Colello

  • Jennifer L. Halpern

  • Herbert S. Schwartz

  • Daniel J. Johnson

  • Jonathan G. Schoenecker

  • Joshua M. Lawrenz

  • June 1, 2026

Share

  • 1

    Tranexamic acid (TXA) is an antifibrinolytic drug used to reduce blood loss and transfusion rates in various orthopedic surgeries.

  • 2

    Patients with cancer have a significantly increased risk of venous thromboembolism (VTE), complicating the use of TXA in this population.

  • 3

    This study analyzed 617 patients who underwent lower extremity endoprosthetic reconstruction for oncologic reasons, assessing TXA's safety and efficacy.

  • 4

    Of the 617 patients, 166 received TXA, with various administration routes including oral and intravenous.

  • 5

    No significant differences were found in baseline characteristics or major comorbidities between TXA-treated and non-TXA-treated patients.

Original Source(s)

Tranexamic Acid in Lower Extremity Endoprosthetic Reconstruction for Oncologic Indications: A Retrospective Comparative Study of 617 Patients

  • by Stephen W. Chenard, Akhil Rekulapelli, Riley S. Gilbertson, Connor S. Charton, William F. Hefley, Michael J. Colello, Jennifer L. Halpern, Herbert S. Schwartz, Daniel J. Johnson, Jonathan G. Schoenecker, Joshua M. Lawrenz

  • June 1, 2026

Related Content

Moving Cancer Survivorship Into Routine Care—Why Are We Still Not Ready for Change?

National Cancer Institute–Supported Obesity and Cancer Research, 2015-2022

Correction: Serial ctDNA dynamics predict clinical outcomes in metastatic and locally advanced PDAC: a systematic review